Ginkgo Bioworks DNA Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | —— | —— | —— | ||
| $141.31M-11.7% | $160.07M-6.1% | $170.52M-22.7% | $220.73M-2.9% | $227.33M+0.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $222.77M-8.6% | $243.77M-9.7% | $270.02M-2.8% | $277.68M-22.6% | $358.53M-15.5% | ||
| $172.08M-1.1% | $173.97M-6.1% | $185.25M-3.8% | $192.59M-10.7% | $215.6M-12.4% | ||
| —— | —— | —— | —— | —— | ||
| -$297.68M+3.1% | -$307.28M+9.7% | -$340.14M-11.4% | -$305.32M+34.0% | -$462.73M+17.3% | ||
| -210.7%-18.7pp | -192%+7.5pp | -199.5%-61.1pp | -138.3%+65.2pp | -203.5%+43.0pp | ||
| —— | —— | —— | —— | —— | ||
| -$298.87M+2.3% | -$305.95M+8.0% | -$332.42M-7.8% | -$308.44M+33.6% | -$464.85M+15.1% | ||
| -$1.01M-20.1% | -$837K-61.3% | -$519K+42.0% | -$895K-112% | -$422K+11.9% | ||
| -$240.72M+3.1% | -$248.29M+11.1% | -$279.16M-15.7% | -$241.34M+39.3% | -$397.75M+19.9% | ||
| -170.3%-15.2pp | -155.1%+8.6pp | -163.7%-54.4pp | -109.3%+65.6pp | -175%+43.8pp | ||
| -$297.68M+3.1% | -$307.28M+9.7% | -$340.14M-11.4% | -$305.32M+34.0% | -$462.73M+17.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Ginkgo Bioworks's revenue?
- Ginkgo Bioworks (DNA) generated $141.3M in revenue over the trailing twelve months, down 37.8% year over year.
- Is Ginkgo Bioworks profitable?
- Ginkgo Bioworks is not currently profitable: it reported a net loss of $304.4M over the trailing twelve months, a -215.4% net margin.
- Where does Ginkgo Bioworks's income statement data come from?
- Every line is extracted from Ginkgo Bioworks's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
